Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) reported Phase 3 INDIGO trial results of obexelimab in IgG4-related disease. The trial met its primary endpoint with a 56% reduction in flare risk vs placebo (HR 0.443; 95% CI 0.277–0.711; p=0.0005) over 52 weeks.
All four key secondary endpoints favored obexelimab with highly statistically significant p-values (0.0001–0.0049). Obexelimab was generally well tolerated: Grade ≥3 treatment-emergent adverse events and serious adverse events occurred less often than with placebo, and no deaths occurred in the obexelimab group.
Zenas BioPharma (Nasdaq: ZBIO) granted an aggregate 51,075 restricted stock units (RSUs) on May 15, 2026 to newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments from May 15, 2027 through May 15, 2030 under the 2026 Inducement Plan.
Zenas BioPharma (Nasdaq: ZBIO) dosed the first subject in a Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor for autoimmune and inflammatory diseases. The study will assess safety, tolerability, and pharmacokinetics in healthy volunteers.
Single and multiple ascending dose data are expected by year-end 2026, with a proof-of-concept psoriasis trial in North America planned thereafter and results anticipated in 2027. Robust preclinical data, including potent IL-17AA/AF inhibition and good oral bioavailability, support ZB021’s potential as a differentiated oral therapy.
Zenas BioPharma (Nasdaq:ZBIO) reported Q1 2026 results and pipeline progress. Obexelimab’s BLA for IgG4-RD is planned for FDA submission this quarter and an EMA MAA in H2 2026, based on Phase 3 INDIGO data showing a 56% reduction in flare risk versus placebo.
SunStone SLE Phase 2 enrollment is complete with topline data expected Q4 2026. First subject was dosed in ZB021 Phase 1, and two Phase 3 orelabrutinib MS trials continue. Year-to-date financings raised $419.0 million; cash and investments were $718.5 million, supporting operations into Q2 2029 assuming specified milestone and debt proceeds.
Q1 2026 R&D expenses were $60.4 million and G&A $16.9 million, with a net loss of $81.0 million.
Zenas BioPharma (Nasdaq: ZBIO) announced that on April 15, 2026 the company granted an aggregate of 41,475 restricted stock units (RSUs) to newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments on April 15, 2027, April 15, 2028, April 15, 2029 and April 15, 2030, and are subject to continued service and the 2026 Inducement Plan.
Zenas BioPharma (Nasdaq: ZBIO) priced concurrent offerings totaling $300.0 million on March 27, 2026: $200.0 million principal of 2.50% convertible senior notes due 2032 and 5,000,000 common shares at $20.00 per share. Zenas expects aggregate net proceeds of approximately $287.5 million to fund the planned U.S. commercial launch of obexelimab if approved, advance orelabrutinib Phase 3 for progressive MS and ZB021 Phase 1/2 development, and for working capital and general corporate purposes. Closing is expected March 31, 2026, subject to customary conditions.
Zenas BioPharma (Nasdaq: ZBIO) commenced registered underwritten public offerings of convertible senior notes due April 1, 2032 and shares of common stock, each with a 30-day 15% over-allotment option. The offerings are separate and not conditioned on one another and are subject to market conditions.
The Company intends to use net proceeds to support a potential U.S. commercial launch of obexelimab for IgG4-RD if approved, advance orelabrutinib Phase 3 trials for progressive multiple sclerosis and ZB021 Phase 1 and 2 development, and for working capital and general corporate purposes.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity grants on March 16, 2026 to newly hired employees: 235,700 stock options and 33,450 RSUs. Options carry a 10-year term and an exercise price of $23.23, equal to the closing price on the grant date.
Options vest over four years (25% at one year, then 36 monthly installments). RSUs vest in four equal annual installments on March 15, 2027–2030 and are subject to continued service and the 2026 Inducement Plan.
Zenas BioPharma (Nasdaq: ZBIO) reported Q4 and full-year 2025 results and a corporate update on March 16, 2026. Key items: obexelimab met INDIGO Phase 3 endpoints with a 56% reduction in IgG4-RD flare risk; BLA submission to FDA expected Q2 2026 and MAA to EMA H2 2026. Company closed a $250M senior secured debt facility with Pharmakon and held $360.5M cash at year-end. Revenue was $10.0M in 2025; net loss was $377.7M for the year.
Zenas BioPharma (Nasdaq: ZBIO) announced inducement grants dated February 17, 2026, awarding newly hired employees 35,700 stock options and 53,625 RSUs. The options carry a $26.77 exercise price, a ten-year term, and multi-year vesting under the company's 2026 Inducement Plan.
Options vest 25% after one year then monthly over three years; RSUs vest in four equal annual installments on Feb 15 each year from 2027–2030.